Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$5.41 USD
-0.03 (-0.55%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Fate Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 315 | 436 | 616 | 483 | 221 |
Receivables | 2 | 38 | 9 | 6 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 27 | 9 | 6 | 6 |
Total Current Assets | 332 | 502 | 633 | 494 | 227 |
Net Property & Equipment | 97 | 110 | 92 | 32 | 11 |
Investments & Advances | 1 | 5 | 101 | 0 | 39 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 15 | 22 | 25 | 29 | 2 |
Total Assets | 506 | 706 | 921 | 622 | 302 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 8 | 9 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 28 | 54 | 42 | 16 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 46 | 25 | 60 | 6 |
Total Current Liabilities | 39 | 114 | 81 | 86 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 27 | 46 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 4 | 25 | 12 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 138 | 222 | 243 | 238 | 58 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,580 | 1,537 | 1,449 | 941 | 628 |
Retained Earnings | -1,212 | -1,051 | -769 | -557 | -384 |
Other Equity | 0 | -2 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 368 | 484 | 679 | 384 | 245 |
Total Liabilities & Shareholder's Equity | 506 | 706 | 921 | 622 | 302 |
Total Common Equity | 368 | 484 | 679 | 384 | 245 |
Shares Outstanding | 98.60 | 97.10 | 95.40 | 87.20 | 75.50 |
Book Value Per Share | 3.74 | 4.98 | 7.12 | 4.41 | 3.24 |
Fiscal Year End for Fate Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 384 | 315 | 350 | 378 |
Receivables | NA | 1 | 2 | 2 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 10 | 15 | 13 | 11 |
Total Current Assets | NA | 394 | 332 | 364 | 392 |
Net Property & Equipment | NA | 92 | 97 | 102 | 106 |
Investments & Advances | NA | 8 | 1 | 0 | 7 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 15 | 15 | 15 | 15 |
Total Assets | NA | 570 | 506 | 544 | 585 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 5 | 6 | 8 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 32 | 28 | 29 | 29 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 1 | 1 | 2 |
Total Current Liabilities | NA | 45 | 39 | 41 | 45 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 144 | 138 | 141 | 147 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,686 | 1,580 | 1,571 | 1,561 |
Retained Earnings | NA | -1,260 | -1,212 | -1,168 | -1,122 |
Other Equity | NA | 0 | 0 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 426 | 368 | 403 | 438 |
Total Liabilities & Shareholder's Equity | NA | 570 | 506 | 544 | 585 |
Total Common Equity | 0 | 426 | 368 | 403 | 438 |
Shares Outstanding | 113.80 | 113.80 | 98.60 | 98.50 | 98.30 |
Book Value Per Share | 0.00 | 3.74 | 3.74 | 4.09 | 4.45 |